Virtual Human Offers Insights Into HIV Drug Efficacy

EU-funded scientists have used a prototype of a Virtual Physiological Human (VPH) to simulate the efficacy of an HIV drug in blocking a key protein used by the virus. The VPH concept involves linking networks of computers from around the world to simulate the inner workings of the human body. With it, scientists can study the effects of a drug and see what is happening at the organ, tissue, cell and molecular levels.

Currently, the VPH is still in the early stages of development, but researchers hope that eventually doctors will be able to use it to develop personalised treatments for their patients.

In this latest study, scientists from University College London (UCL) in the UK ran simulations to predict how strongly the HIV-inhibiting drug saquinavir would bind to three versions of a viral protein called HIV-1 protease. The protein is used by the virus to propagate itself, and mutated forms of the protein are associated with resistance to saquinavir. The results are published in the Journal of the American Chemical Society.

Saquinavir is just one of nine drugs designed to block HIV-1 protease. Currently, doctors have no way to match the drugs to the profile of the virus as it mutates in each patient. Instead, they simply prescribe a course of drugs and see if they are working by analysing the patient's immune response.

In the future, these 'trial and error' methods could be phased out as doctors could use the VPH to see which drugs would be most effective in any given patient. However, the computing power required to run these simulations is immense; for this latest study, the sequence of simulations was carried out across several supercomputers on both the UK's National Grid Service and the US TeraGrid.

The work took two weeks and used the same amount of computing power as that needed to perform a long-range weather forecast. The scientists hope that in the future, technological advances could bring down the costs of carrying out such simulations so that health services can afford to pay for them.

"This study represents a first step towards the ultimate goal of 'on-demand' medical computing, where doctors could one day 'borrow' supercomputing time from the national grid to make critical decisions on life-saving treatments," explained Professor Peter Coveney of UCL, who led the research.

"For example, for an HIV patient, a doctor could perform an assay to establish the patient's genotype and then rank the available drugs' efficacy against that patient's profile based on a rapid set of large-scale simulations, enabling the doctor to tailor the treatment accordingly."

Professor Coveney and his team are now looking at all the protease inhibitor drugs in the same way.

EU support for the study came from the ViroLab (A virtual laboratory for decision support in viral diseases treatment) project, which is funded under the Information society technologies thematic area of the Sixth Framework Programme.

Meanwhile, Professor Coveney is also involved in the VPH Initiative, which has received €72 million from the Seventh Framework Programme (FP7). The initiative aims to boost collaboration between clinicians and scientists to explore the possibilities of patient-specific medical treatments based on the latest modelling and simulation methods.

For further information, please visit:

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

AI-Powered CRISPR could Lead to Faster G…

Stanford Medicine researchers have developed an artificial intelligence (AI) tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing “copilot” supported by AI to help...

Groundbreaking AI Aims to Speed Lifesavi…

To solve a problem, we have to see it clearly. Whether it’s an infection by a novel virus or memory-stealing plaques forming in the brains of Alzheimer’s patients, visualizing disease processes...

AI Spots Hidden Signs of Depression in S…

Depression is one of the most common mental health challenges, but its early signs are often overlooked. It is often linked to reduced facial expressivity. However, whether mild depression or...

ChatGPT 4o Therapeutic Chatbot 'Ama…

One of the first randomized controlled trials assessing the effectiveness of a large language model (LLM) chatbot 'Amanda' for relationship support shows that a single session of chatbot therapy...

AI Tools Help Predict Severe Asthma Risk…

Mayo Clinic researchers have developed artificial intelligence (AI) tools that help identify which children with asthma face the highest risk of serious asthma exacerbation and acute respiratory infections. The study...

AI Model Forecasts Disease Risk Decades …

Imagine a future where your medical history could help predict what health conditions you might face in the next two decades. Researchers have developed a generative AI model that uses...

AI Distinguishes Glioblastoma from Look-…

A Harvard Medical School–led research team has developed an AI tool that can reliably tell apart two look-alike cancers found in the brain but with different origins, behaviors, and treatments. The...

Smart Device Uses AI and Bioelectronics …

As a wound heals, it goes through several stages: clotting to stop bleeding, immune system response, scabbing, and scarring. A wearable device called "a-Heal," designed by engineers at the University...

AI Model Indicates Four out of Ten Breas…

A project at Lund University in Sweden has trained an AI model to identify breast cancer patients who could be spared from axillary surgery. The model analyses previously unutilised information...

Overcoming the AI Applicability Crisis a…

Opinion Article by Harry Lykostratis, Chief Executive, Open Medical. The government’s 10 Year Health Plan makes a lot of the potential of AI-software to support clinical decision making, improve productivity, and...

Dartford and Gravesham Implements Clinis…

Dartford and Gravesham NHS Trust has taken a significant step towards a more digital future by rolling out electronic test ordering using Clinisys ICE. The trust deployed the order communications...